Ricardo Cordido, MD
Cardiovascular Disease · Hamden, CTNPI 1003806456
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $105,884 of the $135,204 with a category attached, or 78.3%. 44 manufacturers reported payments, led by Johnson & Johnson at 50.9% of the total. Reporting peaked in 2019 at $58,948 and has fallen 95.8% since, to $2,497 in 2025. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 807 payments — averaging $167.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$69K
- Amgen$18K
- Merck$15K
- Novartis$15K
- Medtronic$9K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $8K from 38 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$105,88478%
- Travel & lodging$6,7275%
- Food & beverage$21,97816%
- Education$3150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$135,204 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 306 | $366,706 |
| EliquisApixaban | 240 | $301,466 |
| EntrestoSacubitril/Valsartan | 98 | $164,199 |
| Repatha SureclickEvolocumab | 63 | $71,940 |
| FarxigaDapagliflozin Propanediol | 39 | $56,297 |
| BrilintaTicagrelor | 20 | $23,655 |
| VerquvoVericiguat | 18 | $18,860 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 41 | $18,251 |
| EdarbiAzilsartan Medoxomil | 27 | $15,415 |
| LivaloPitavastatin Calcium | 20 | $14,874 |
| VascepaIcosapent Ethyl | 31 | $13,654 |
| Ranolazine ErRanolazine | 70 | $9,570 |
| Nebivolol Hcl | 130 | $8,382 |
| Rosuvastatin Calcium | 485 | $5,538 |
| Olmesartan Medoxomil | 293 | $4,574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $68,811 | $366,706306 claims |
| PfizerEliquis | $528 | $301,466240 claims |
| NovartisEntresto | $14,778 | $164,19998 claims |
| AstraZenecaFarxiga, Brilinta | $959 | $79,95259 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $121 | $33,66668 claims |
| MerckVerquvo | $15,330 | $18,86018 claims |
| Kowa Pharmaceuticals America, Inc.Livalo, Bystolic | $148 | $17,84831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Hamden
- Louis TelesfordHamden$34K
- Marian VulpeHamden$15K
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- Stephanie SaucierHartford$243K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Antonio FernandezHartford$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.